STOCKS NEWS EUROPE-BTG falls on sales setback

Shares in BTG (BGC.L) fall 5 percent after the British speciality pharmaceutical company suffers a setback to sales of its anti-poison drugs, and following delays in some of its pipeline products.

"Given that they had problems with the manufacturing of CroFab and DigiFab, that might be a concern, those sales were certainly lighter than we were expecting," says Jefferies analyst Philippa Gardner.

"A couple of potential catalysts have slipped back, Voraxaze Biologics License Application filing is now almost a year later," adds Gardner, who has a "hold" rating on the stock and a 210 pence per share price target.

To see the full article please click on [ID:nL5366304]

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net